WORCESTER, Mass., July 9, 2008 (PRIME NEWSWIRE) -- An Investigational New Drug application (IND) has been submitted to the United States Food and Drug Administration (FDA) on behalf of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) for its AE37 immunotherapeutic vaccine combined with a vaccine peptide that works by a different mechanism for patients. The immunotherapeutic cancer vaccine AE37 is being developed through Antigen Express, Inc. (www.antigenexpress.com), the wholly owned immunotherapeutics subsidiary of Generex.
